Immuron Limited (AU:IMC) has released an update.
Immuron Limited’s CEO, Steven Lydeamore, is set to present at the Sharewise conference on July 9, 2024, showcasing the company’s advancements in biopharmaceuticals, including their flagship product, Travelan®, which is designed to combat travelers’ diarrhea. The company’s proprietary technology produces targeted polyclonal antibodies for infectious diseases, with promising results in pre-clinical trials for preventing and treating conditions like Clostridioides difficile infection.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
